About Prolong Pharma
Prolong Pharma is a Healthcare company based in South Plainfield (United States) founded in 2005. Products for hematology and oncology indications are developed. Prolong Pharma has raised $30 million across 4 funding rounds from investors including HHS and Tarsadia. The company has 3 employees. Prolong Pharma offers products and services including Sanguinate® and PEGfinity. Its focus areas include Diversified Pharmaceuticals. Its legal entity is PROLONG PHARMACEUTICALS, LLC.
Company details
Founded in 2005, Prolong Pharmaceuticals is based in South Plainfield, United States, within the biopharmaceutical sector. Focus is placed on developing therapies for hematology and oncology, including Sanguinate for sickle cell disease comorbidities related to ischemia, hypoxia, and hemolysis. EPEG, a PEGylated EPO biologic, is advanced in clinical trials for anemia associated with chronic kidney disease and cancer chemotherapy. PP-403, a novel cytokine, is explored for cancer applications.
- Headquarters South Plainfield, United States
- Employees 3
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website prolongpharma.com
- Social LinkedIn
- Legal Name Prolong Pharmaceuticals, Llc
- Total Equity Funding$30M (USD)
in 4 rounds
- Latest Funding Round$30M (USD), Series C
Oct 2010
- InvestorsHHS
& 1 more
- Employee Count3
Products & Services of Prolong Pharma
Prolong Pharma offers a comprehensive portfolio of products and services, including Sanguinate® and PEGfinity.
Delivers oxygen to hypoxic tissue and reduces inflammation in diseases.
Generates and optimizes protein leads for enhanced stability.
Funding Insights of Prolong Pharma
Prolong Pharma has successfully raised a total of $30M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 4
- Last Round Series C — $30M
- First Round $1.01M
(Sep 2008)
- Investors Count 2
All 4 funding rounds of Prolong Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Prolong Pharma
Prolong Pharma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and Tarsadia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity are directed toward multiple sectors. | tarsadia.com | Newport Beach, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Prolong Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Prolong Pharma
8 people are tracked at Prolong Pharma (4 in leadership, 4 in team); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Nikunj Patel | President | Leadership |
Chandra Rawal | Head Of Operations | Leadership |
Keith O'Hare | Associate Director, Manufacturing | Leadership |
Ron Jubin | VP, R&D | Leadership |
Vito Terranova | Microbiologist | Team |
Pragna Raval | Senior Scientist | Team |
Nicole Basile | Executive Assistant | Team |
Rosemary Mayer-Ezell | Scientific Researcher | Team |
Complete people profiles for Prolong Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Prolong Pharma
3 dated milestones of Prolong Pharma across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Prolong Pharma is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series C, of $30.0M.
Web traffic of Prolong Pharma
The website of Prolong Pharma (prolongpharma.com) receives about 3.8K visits a month and ranks #13,715,654 among all websites worldwide, #8,483 in Biotechnology and Pharmaceuticals.
- Monthly visits3.8K
▲ 246.6% vs previous month
- Global rank#13,715,654
among all websites
- Category rank#8,483
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.2
- Average visit13 sec
- DevicesDesktop 51% · Mobile 49%
Websites whose visitors overlap most with Prolong Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sklifescienceinc.com | 100% | #3,520,400 | View details | ||
sanatatenaturala.ro | sanatatenaturala.ro | 47% | – | ||
salcobrand.cl | salcobrand.cl | 31% | #17,769 | – | |
| farmaciasahumada.cl | 31% | 1.7M | #34,019 | View details | |
| nexomics.com | 31% | 1.3K | #11,468,977 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Prolong Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Prolong Pharma (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prolong Pharma
Complete news archive for Prolong Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prolong Pharma
Prolong Pharma was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Prolong Pharma is headquartered in South Plainfield, United States. It is registered at South Plainfield, New Jersey, United States.
Prolong Pharma is a funded company, having raised a total of $30M across 4 funding rounds to date. The company's 1st funding round was a Grant of $1.01M, raised on Sep 2008.
Prolong Pharma has 3 employees.
Founded in 2005, Prolong Pharmaceuticals is based in South Plainfield, United States, within the biopharmaceutical sector. Focus is placed on developing therapies for hematology and oncology, including Sanguinate for sickle cell disease comorbidities related to ischemia, hypoxia, and hemolysis. EPEG, a PEGylated EPO biologic, is advanced in clinical trials for anemia associated with chronic kidney disease and cancer chemotherapy. PP-403, a novel cytokine, is explored for cancer applications.
Prolong Pharma offers Sanguinate® and PEGfinity.
Prolong Pharma operates through Prolong Pharmaceuticals, Llc.